|
|
|
|
|
|
|
|
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models:
July 2012 doi:10.1038/bjc.2012.261
Background:
Bevacizumab is being
incorporated as first-line therapy with standard-of-care chemotherapy on
epithelial ovarian carcinoma (EOC). We investigated bevacizumab
combined with chemotherapy on tumour progression and mouse survival in
EOC xenograft models.
Methods:
Bevacizumab was administered concomitantly with cisplatin plus paclitaxel (DDP+PTX),
continued after induction (maintenance) or started after chemotherapy.
The effect on tumour progression was monitored by bioluminescence
imaging (BLI) (1A9-luc xenograft). Tumour dissemination into the
peritoneal organs and ascites formation (HOC22 xenograft) was evaluated
by histological analysis at the end of treatment (interim) and at
euthanasia (survival). The effects on overall survival (OS) were
investigated in both EOC models.
Results:
Bevacizumab with PTX+DDP
delayed tumour progression in mice bearing EOC xenografts. OS was
significantly extended, with complete responses, by bevacizumab
continued after stopping chemotherapy in the HOC22 xenograft.
Bevacizumab alone inhibited ascites formation, with only limited effect
on tumour burden, but combined with PTX+DDP reduced ascites and metastases. Bevacizumab started after induction with PTX+DDP and maintained was equally effective on tumour progression and survival on 1A9-luc xenograft.
Conclusion:
Bevacizumab
combined with chemotherapy not only affected tumour progression, but
when administered as maintenance regimen significantly prolonged
survival, reducing ascites, and tumour dissemination. We believe our
findings are consistent with the clinical results and shed light on the
potential effects of this kind of treatment on tumour progression.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.